June 19, 2020 / 11:34 AM / 13 days ago

BRIEF-Sanofi Says Dupixent® Approved In China For Adults With Moderate-To-Severe Atopic Dermatitis

June 19 (Reuters) - Sanofi SA:

* REG-DUPIXENT® (DUPILUMAB) APPROVED IN CHINA FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

* DUPIXENT INCLUDED IN CHINA’S LIST OF OVERSEAS APPROVED DRUGS THAT MEET URGENT CLINICAL NEED

* DUPIXENT INCLUDED IN CHINA’S LIST OF OVERSEAS APPROVED DRUGS THAT MEET URGENT CLINICAL NEED

* DUPIXENT IS APPROVED IN 60 COUNTRIES FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS, ONE OF DISEASES DRIVEN BY TYPE 2 INFLAMMATION

* CHINA CONTINUES TO BE A SIGNIFICANT AREA OF GROWTH FOR US

* WE PLAN TO SEEK APPROVAL BY 2025 FOR MORE THAN 25 INNOVATIVE MEDICINES FOR CHRONIC AND RARE DISEASES AND VACCINES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below